Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

MNMarcel NijlandJLJennifer Lord‐BessenRKRajesh Kamalakar

Discussion

Loading...

Member takes

Overview

Efficacy of epcoritamab and rituximab improves health-related quality of life in relapsed lymphoma, indicating manageable adverse events.

Key Points

  • Patients maintained high quality of life despite higher adverse events with the epcoritamab regimen.
  • Complete response rates were 75% for epcoritamab in dosage of 48 mg compared to 43% for rituximab.
  • Adverse events were noted in 88% of epcoritamab patients, still presenting manageable safety profile.
  • The linear mixed-effect model showed similar quality of life between both treatment arms at all time points.

Cite This Study

Nijland et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e00ahttps://doi.org/10.1182/blood-2025-5370
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma2025 · 2 citations
  2. 2Fixed-Duration Epcoritamab Plus R2 Drives Favorable Outcomes in Relapsed or Refractory Follicular Lymphoma2025
  3. 3Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 72025 · 1 citations
  4. 4Optimal dose regimen of epcoritamab in combination with lenalidomide and rituximab in relapsed or refractory follicular lymphoma - analyses of pharmacokinetics and exposure-response relationships of epcore FL-1 Phase 3 study2025
  5. 5Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial2025